The award provides reputational validation but does not alter Evaxion's clinical or funding timeline. Monitor upcoming clinical data readouts and capital-raising events, as the company's $30M market cap and clinical-stage status imply continued cash needs. No immediate trading catalyst from this release.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 12 $3.64entry
- T+1 · 5mo ago −1.10%α −2.86% · $3.60
- T+5 · 5mo ago −16.21%α −16.88% · $3.05
- T+20 · 4mo ago −12.91%α −14.69% · $3.17
- T+60 · 2mo ago −12.91%α −16.18% · $3.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion receives the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform. While this is the second Galien recognition in under a year, it is a non-financial, reputational award that does not change the company's clinical or financial trajectory. The filing contains no revenue, EPS, guidance, or other material financial data.
Key Facts
- Evaxion awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology.
- This is the second recognition from the Prix Galien Foundation in less than a year (previous award in Dec 2025).
- Evaxion is a clinical-stage TechBio company with no revenue or financial data disclosed in this release.
- The award committee comprised 12 experts who evaluated innovation, clinical application, and utility.
Financial Impact
No financial figures disclosed; the award has no immediate revenue or cash impact.
Risk Factors
- Clinical-stage company with no approved products or disclosed revenue, high cash burn risk.
- Award has no direct impact on pipeline progression or regulatory milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310899 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers